Taek-Sung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taek-Sung Kim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Cheol-Jung Yang
Department of Orthopedic Surgery, Borntouch Orthopaedic Clinic, Seoul, Korea
2 shared publications - Eun-Ae Kim
Department of Health Education, Korea National Sport University
2 shared publications - Hae-Jung Oh
Department of Health Education, Korea National Sport University
2 shared publications - Jeong Won Seong
Department of Family Medicine, Sarang Clinic, Jinju, Korea
2 shared publications - Kook-Hee An
Department of Measurement and Evaluation, Korea National Sport University
2 shared publications - Sin-Hye Park
Department of Food Science and Nutrition and Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 19, 1-6
Tendon Traction Point Therapy for Medial Knee Pain in an Elite Badminton Player: A Case Report
Medial knee pain in elite athletes is often attributed to structural lesions such as medial meniscus tears; however, imaging findings do not always correspond to the primary pain generator. We report a 20-year-old elite badminton player diagnosed with a partial tear of the medial meniscus posterior horn (MMPH) who presented with severe medial knee pain and was initially recommended for surgical treatment. Detailed clinical evaluation suggested that the patient’s symptoms were more consistent with pes anserinus-related pathology involving the sartorius, gracilis, and semitendinosus (SGS) tendon complex. Under ultrasound guidance, four weekly injections of 5 mL 5% dextrose were administered into the tendon traction points (TTP) of the sartorius, gracilis, and semitendinosus muscles. Pain scores markedly improved from 8 to 1 on the Visual Analog Scale (VAS), with rapid recovery of function and full return to competition without surgical intervention. At two-month follow-up, the athlete reported minimal residual discomfort without any functional limitations. This case highlights the importance of identifying the true pain generator in medical knee pain and demonstrates that TTP injection therapy is a safe, steroid-free, and minimally invasive non-surgical alternative, particularly in athletes where rapid return to play is critical.
- 1 April 2026
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 19, 1-6
Open AccessTendon Traction Point Therapy for Medial Knee Pain in an Elite Badminton Player: A Case Report
Medial knee pain in elite athletes is often attributed to structural lesions such as medial meniscus tears; however, imaging findings do not always correspond to the primary pain generator. We report a 20-year-old elite badminton player diagnosed with a partial tear of the medial meniscus posterior horn (MMPH) who presented with severe medial knee pain and was initially recommended for surgical treatment. Detailed clinical evaluation suggested that the patient’s symptoms were more consistent with pes anserinus-related pathology involving the sartorius, gracilis, and semitendinosus (SGS) tendon complex. Under ultrasound guidance, four weekly injections of 5 mL 5% dextrose were administered into the tendon traction points (TTP) of the sartorius, gracilis, and semitendinosus muscles. Pain scores markedly improved from 8 to 1 on the Visual Analog Scale (VAS), with rapid recovery of function and full return to competition without surgical intervention. At two-month follow-up, the athlete reported minimal residual discomfort without any functional limitations. This case highlights the importance of identifying the true pain generator in medical knee pain and demonstrates that TTP injection therapy is a safe, steroid-free, and minimally invasive non-surgical alternative, particularly in athletes where rapid return to play is critical.
- Open Access
- 18 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2562308
A novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case report
Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies. We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period. Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit. This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.
- 18 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2562308
Open AccessA novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case report
Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies. We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period. Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit. This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.